{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:08:14Z","timestamp":1772179694539,"version":"3.50.1"},"reference-count":41,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title>\n                  <jats:p>Premature infants have a higher risk of invasive pneumococcal disease and are more likely to have lower vaccine responses compared with term infants. Increasingly, immunization schedules are including a reduced, 2-dose, pneumococcal conjugate vaccine priming schedule. Our goal was to assess the immunogenicity of 3 commonly used 13-valent pneumococcal conjugate vaccine (PCV13) priming schedules in premature infants and their response to a 12-month booster dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Premature infants (&amp;lt;35 weeks\u2019 gestation) were randomized to receive PCV13 at 2 and 4 months (reduced schedule); 2, 3, and 4 months (accelerated schedule); or 2, 4, and 6 months (extended schedule). All infants received a 12-month PCV13 booster. Serotype-specific pneumococcal immunoglobulin G (IgG) for PCV13 serotypes was measured by using enzyme-linked immunosorbent assay 1 month after the primary and booster vaccinations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>A total of 210 infants (median birth gestation, 29+6 weeks; range, 23+2\u201334+6 weeks) were included. After the primary vaccination, 75% (95% confidence interval [CI], 62\u201385), 88% (95% CI, 76\u201395), and 97% (95% CI, 87\u201399) of participants had protective antibody concentrations for at least one-half the PCV13 serotypes for the reduced, accelerated, and extended schedules, respectively. After the booster vaccination, participants receiving the extended schedule had significantly lower (P &amp;lt; .05) geometric mean concentrations compared with reduced (for 9 of 13 serotypes) and accelerated (for 4 of 13 serotypes) schedules, but nearly all participations, regardless of schedule or serotype, had seroprotective IgG concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>A reduced priming schedule of PCV13 resulted in higher post-booster IgG concentrations but lower post-primary concentrations. The optimum vaccine schedule for preterm infants will therefore depend on when they are most at risk for invasive pneumococcal disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2015-3945","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T09:07:22Z","timestamp":1470647242000},"source":"Crossref","is-referenced-by-count":27,"title":["Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT"],"prefix":"10.1542","volume":"138","author":[{"given":"Alison","family":"Kent","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases Research Group and Vaccine Institute, St George\u2019s, University of London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Immunization, Hepatitis and Blood Safety Department and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick J.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Statistics, Modelling and Economics Department, Public Health England, Colindale, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Scorrer","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Queen Alexandra Hospital, Portsmouth, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Clarke","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Immunology, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Heal","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Stepping Hill Hospital, Stockport, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esse","family":"Menson","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Evelina London Children\u2019s Hospital, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chang","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Croydon University Hospital, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Satodia","sequence":"additional","affiliation":[{"name":"Neonatal Unit, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Collinson","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Royal Cornwall Hospital, Truro, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul N.","family":"Faust","sequence":"additional","affiliation":[{"name":"NIHR Welcome Trust Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Goldblatt","sequence":"additional","affiliation":[{"name":"Institute of Child Health, UCL, London, England"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[{"name":"Immunization, Hepatitis and Blood Safety Department and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group and Vaccine Institute, St George\u2019s, University of London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the PUNS Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"2021120907151956800_B1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2334-10-12","article-title":"Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants.","volume":"10","author":"R\u00fcckinger","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"8","key":"2021120907151956800_B2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1086\/512814","article-title":"Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study.","volume":"44","author":"Hjuler","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2021120907151956800_B3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00006454-200203000-00003","article-title":"Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants.","volume":"21","author":"Shinefield","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2021120907151956800_B4","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/INF.0b013e3181faa6be","article-title":"Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2021120907151956800_B5","doi-asserted-by":"crossref","first-page":"e74906","DOI":"10.1371\/journal.pone.0074906","article-title":"Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.","volume":"8","author":"Grant","year":"2013","journal-title":"PLoS One"},{"issue":"49","key":"2021120907151956800_B6","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1016\/j.vaccine.2011.09.112","article-title":"Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.","volume":"29","author":"Miller","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"2021120907151956800_B7","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2014-2941","article-title":"13-Valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.","volume":"135","author":"Martin\u00f3n-Torres","year":"2015","journal-title":"Pediatrics"},{"issue":"2","key":"2021120907151956800_B8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.vaccine.2006.07.036","article-title":"Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants.","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"2021120907151956800_B9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00214-10","article-title":"Responses to a conjugate pneumococcal vaccine in preterm infants immunized at 2, 3, and 4 months of age.","volume":"17","author":"Moss","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"2021120907151956800_B10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/adc.2005.086306","article-title":"Immunisation of premature infants.","volume":"91","author":"Bonhoeffer","year":"2006","journal-title":"Arch Dis Child"},{"issue":"6","key":"2021120907151956800_B11","doi-asserted-by":"crossref","first-page":"e1001839","DOI":"10.1371\/journal.pmed.1001839","article-title":"The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries.","volume":"12","author":"Flasche","year":"2015","journal-title":"PLoS Med"},{"issue":"6","key":"2021120907151956800_B12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/21645515.2015.1019189","article-title":"Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?","volume":"11","author":"Findlow","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"18","key":"2021120907151956800_B13","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.vaccine.2010.02.065","article-title":"Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.","volume":"28","author":"Russell","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"2021120907151956800_B14","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","article-title":"Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.","volume":"179","author":"Richmond","year":"1999","journal-title":"J Infect Dis"},{"issue":"10","key":"2021120907151956800_B15","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1128\/IAI.71.10.5549-5555.2003","article-title":"Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.","volume":"71","author":"Borrow","year":"2003","journal-title":"Infect Immun"},{"key":"2021120907151956800_B16","doi-asserted-by":"crossref","first-page":"h1554","DOI":"10.1136\/bmj.h1554","article-title":"Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.","volume":"350","author":"Pace","year":"2015","journal-title":"BMJ"},{"key":"2021120907151956800_B17","unstructured":"Public Health England\n          . Contraindications and special considerations (Chapter 6). Immunisation against infectious disease: the green book. Available at: https:\/\/www.gov.uk\/government\/publications\/contraindications-and-special-considerations-the-green-book-chapter-6. Published March 20, 2013. Updated April 4, 2013. Accessed January 31, 2016"},{"key":"2021120907151956800_B18","first-page":"266","article-title":"Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.","volume":"8(2)","author":"Concepcion","year":"2001","journal-title":"Clin Vaccine Immunol"},{"issue":"23","key":"2021120907151956800_B19","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.","volume":"21","author":"J\u00f3dar","year":"2003","journal-title":"Vaccine"},{"issue":"5","key":"2021120907151956800_B20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/INF.0b013e3181c67f04","article-title":"Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom.","volume":"29","author":"Goldblatt","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021120907151956800_B21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.inf.0000207483.60267.e7","article-title":"Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.","volume":"25","author":"Goldblatt","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2021120907151956800_B22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.vaccine.2014.12.018","article-title":"Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.","volume":"33","author":"Ladhani","year":"2015","journal-title":"Vaccine"},{"key":"2021120907151956800_B23","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/INF.0000000000000079","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.","volume":"33","author":"Deloria Knoll","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"52","key":"2021120907151956800_B24","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1016\/j.vaccine.2011.07.042","article-title":"Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis.","volume":"29","author":"Scott","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"2021120907151956800_B25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ni0311-189","article-title":"Challenges in infant immunity: implications for responses to infection and vaccines.","volume":"12","author":"PrabhuDas","year":"2011","journal-title":"Nat Immunol"},{"issue":"3","key":"2021120907151956800_B26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age.","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2021120907151956800_B27","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2013.228052","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.","volume":"310","author":"Spijkerman","year":"2013","journal-title":"JAMA"},{"issue":"20\u201321","key":"2021120907151956800_B28","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/S0264-410X(99)00048-1","article-title":"Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid.","volume":"17","author":"\u00c5hman","year":"1999","journal-title":"Vaccine"},{"issue":"42","key":"2021120907151956800_B29","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1016\/j.vaccine.2005.05.028","article-title":"Attenuated immune response to tetanus toxoid in young healthy men protected against tetanus.","volume":"23","author":"Danilova","year":"2005","journal-title":"Vaccine"},{"issue":"12","key":"2021120907151956800_B30","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.vaccine.2004.09.020","article-title":"Short-term booster effect of diphtheria toxoid in initially long-term protected individuals.","volume":"23","author":"Danilova","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"2021120907151956800_B31","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4049\/jimmunol.180.4.2165","article-title":"The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.","volume":"180","author":"Blanchard Rohner","year":"2008","journal-title":"J Immunol"},{"issue":"45","key":"2021120907151956800_B32","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1016\/j.vaccine.2011.08.076","article-title":"Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.","volume":"29","author":"Andrews","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"2021120907151956800_B33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jpeds.2007.09.034","article-title":"Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants.","volume":"152","author":"Knuf","year":"2008","journal-title":"J Pediatr"},{"issue":"1","key":"2021120907151956800_B34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clim.2012.08.006","article-title":"The developing human preterm neonatal immune system: a case for more research in this area.","volume":"145","author":"Sharma","year":"2012","journal-title":"Clin Immunol"},{"issue":"11","key":"2021120907151956800_B35","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/657143","article-title":"Profound lack of interleukin (IL)-12\/IL-23p40 in neonates born early in gestation is associated with an increased risk of sepsis.","volume":"202","author":"Lavoie","year":"2010","journal-title":"J Infect Dis"},{"issue":"2","key":"2021120907151956800_B36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2249.2002.01920.x","article-title":"Phenotypic and functional analysis of human T lymphocytes in early second- and third-trimester fetuses.","volume":"129","author":"Zhao","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"2021120907151956800_B37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2249.2005.02767.x","article-title":"Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed by single platform flow cytometry.","volume":"140","author":"Berrington","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"2021120907151956800_B38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.imbio.2011.07.027","article-title":"Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth.","volume":"217","author":"McGreal","year":"2012","journal-title":"Immunobiology"},{"issue":"1","key":"2021120907151956800_B39","doi-asserted-by":"crossref","first-page":"F57","DOI":"10.1136\/fn.89.1.F57","article-title":"Acellular pertussis vaccine given by accelerated schedule: response of preterm infants.","volume":"89","author":"Slack","year":"2004","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"34","key":"2021120907151956800_B40","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1016\/j.vaccine.2014.03.017","article-title":"Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.","volume":"32","author":"van Hoek","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"2021120907151956800_B41","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3945\/1098078\/peds_20153945.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3945\/1098078\/peds_20153945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:46:07Z","timestamp":1639100767000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/138\/3\/e20153945\/52713\/Schedules-for-Pneumococcal-Vaccination-of-Preterm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,9,1]]},"published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-3945","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]},"article-number":"e20153945"}}